Galmed Pharmaceuticals (GLMD) Depreciation & Amortization (CF) (2013 - 2024)
Galmed Pharmaceuticals (GLMD) posted quarterly Depreciation & Amortization (CF) of $74000.0 for Q2 2024, up 722.22% year-over-year from $9000.0 in Q3 2023, and up 722.22% quarter-over-quarter from $9000.0 in Q1 2024.
Galmed Pharmaceuticals (GLMD) Depreciation & Amortization (CF) (2013 - 2024) Analysis & Trends
Galmed Pharmaceuticals' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $74000.0 for Q2 2024.
- In Q2 2024, Depreciation & Amortization (CF) rose 722.22% year-over-year to $74000.0; the TTM figure through Mar 2025 stood at $74000.0 (up 131.25% YoY), while the FY2025 annual figure was $21000.0, down 74.7% from the prior year.
- Depreciation & Amortization (CF) for Q2 2024 stood at $74000.0, up from $9000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $74000.0 in Q2 2024, with the low at $6000.0 in Q4 2023.
- The 5-year median for Depreciation & Amortization (CF) is $9000.0 (2020), against an average of $12777.8.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) plunged 33.33% in 2023, then jumped 722.22% in 2024.
- Galmed Pharmaceuticals' Depreciation & Amortization (CF) stood at $11000.0 in 2020, then dropped by 9.09% to $10000.0 in 2021, then declined by 10.0% to $9000.0 in 2022, then plunged by 33.33% to $6000.0 in 2023, then jumped by 1133.33% to $74000.0 in 2024.
- Business Quant data shows GLMD's Depreciation & Amortization (CF) at $74000.0 in Q2 2024, $9000.0 in Q1 2024, and $6000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 74,000.00 |
| Jun 30, 2024 | 74,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 9,000.00 |
| Dec 31, 2022 | 9,000.00 |
| Sep 30, 2022 | 8,000.00 |
| Sep 30, 2022 | 8,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Mar 31, 2022 | 9,000.00 |